GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Research & Development

Taiko Pharmaceutical Co (TSE:4574) Research & Development : 円0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Taiko Pharmaceutical Co's Research & Development for the three months ended in Mar. 2024 was 円0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was 円0 Mil.


Taiko Pharmaceutical Co Research & Development Historical Data

The historical data trend for Taiko Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Research & Development Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Taiko Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Taiko Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taiko Pharmaceutical Co  (TSE:4574) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Taiko Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiko Pharmaceutical Co (TSE:4574) Business Description

Traded in Other Exchanges
N/A
Address
No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines